The present invention relates to antiviral agents according to Formula I and their use in the treatment of viral infection.

##STR00001##

The present invention relates to antiviral agents according to Formula I and their use in the treatment of viral infection.

##STR00001##

A solvent extraction process for desalination of seawater. The process uses a special class of polar organic solvents to preferentially dissolve salt-free water from salty water, which exhibits a reverse solubility-temperature behavior (i.e., the solubility of water in the solvent is high at room temperature but significantly lower at higher temperatures). The desalination process includes adding these special class of solvents to sea or salty water at room temperature, separating the solvent-water phase (organic phase) from the remaining mass of salt-rich water (aqueous phase), heating the solvent-water phase to a higher temperature and recovering the relatively salt-free water that separates out. The process is simple, fast, ecologically safe and energy efficient.

A solvent extraction process for desalination of seawater. The process uses a special class of polar organic solvents to preferentially dissolve salt-free water from salty water, which exhibits a reverse solubility-temperature behavior (i.e., the solubility of water in the solvent is high at room temperature but significantly lower at higher temperatures). The desalination process includes adding these special class of solvents to sea or salty water at room temperature, separating the solvent-water phase (organic phase) from the remaining mass of salt-rich water (aqueous phase), heating the solvent-water phase to a higher temperature and recovering the relatively salt-free water that separates out. The process is simple, fast, ecologically safe and energy efficient.

Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

There is disclosed a method for preparing levetiracetam and intermediates from a compound of the formula:

##STR00001##

wherein CR is selected from the group consisting of cyano, carboxylic acid, carboxamide, alkali carboxylate, alkaline earth metal carboxylate, alkyl carboxylate, and a mixture thereof.

There is disclosed a method for preparing levetiracetam and intermediates from a compound of the formula:

##STR00001##

wherein CR is selected from the group consisting of cyano, carboxylic acid, carboxamide, alkali carboxylate, alkaline earth metal carboxylate, alkyl carboxylate, and a mixture thereof.

The present invention relates to a bifunctional chiral organocatalytic compound having excellent enantioselectivity, a preparation method therefor, and a method for producing a non-natural gamma amino acid from a nitro compound by using the chiral organocatalytic compound. According to the present invention, the bifunctional chiral organocatalytic compound having excellent enantioselectivity can be easily synthesized, gamma-amino acids with high optical selectivity can be obtained at a high yield by an economical and convenient method using the chiral organocatalytic compound, and various (R)-configuration gamma-amino acids, which are not present in nature, can be produced with high optical purity in large quantities by using a small amount of a catalyst, and therefore, the present invention can be widely utilized in various industrial fields including the pharmaceutical industry.

A process can be used to produce N-vinyl compounds by homogeneous catalysis. In the process, acetylene is reacted with a cyclic compound having at least one nitrogen as a ring member, hearing a substitutable hydrogen residue (cyclic compound C), in a liquid phase in the presence of a ruthenium complex containing at least one phosphine as a ligand (RuCat).

A process can be used to produce N-vinyl compounds by homogeneous catalysis. In the process, acetylene is reacted with a cyclic compound having at least one nitrogen as a ring member, hearing a substitutable hydrogen residue (cyclic compound C), in a liquid phase in the presence of a ruthenium complex containing at least one phosphine as a ligand (RuCat).